Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Lung Neoplasms 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ductal, Breast 2Adenocarcinoma Of Esophagus 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1The Neoadjuvant Therapy 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Seminoma 1Recurrence 1Primary Malignant Neoplasm of Ovary 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1

Interventions

trametinib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Paclitaxel 1Letrozole 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Cystadenocarcinoma, Serous × Paclitaxel × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡